The following is a summary of “Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer,” published in ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's ...

Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Researchers have discovered a particular type of cancer cell that relies on its own biological electric utility company to thrive. Disrupting this power plant – with the help of a puffer fish – showed ...

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response critical for their elimination.

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...